{"url_path":"/sec/tlsiw/8-k/2026-05-12/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Conditions.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1826667/0001628280-26-034082-index.html","accession_number":"0001628280-26-034082","cik":"0001826667","ticker":"TLSI","issuer_name":"TriSalus Life Sciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1826667/0001628280-26-034082-index.html","primary_entity_key":"0001826667","primary_entity_name":"TriSalus Life Sciences, Inc."},"word_count":128,"has_tables":true,"body_markdown":"Item 2.02Results of Operations and Financial Conditions.\n\nOn May 12, 2026, TriSalus Life Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.\n\nThis information, including Exhibit 99.1, will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and it will not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in any such filing."}